Table 4.
Target | Clinical parameter | LUMC serum | UCL serum | UNEW serum | UCL plasma | ||||||||
Samples | ρ | P-value | Samples | ρ | P-value | Samples | ρ | P-value | Samples | ρ | P-value | ||
CK | NSAA score | 25 | 0.56 | 0.004 | 22 | –0.54 | 0.009 | 45 | 0.31 | 0.037 | 24 | –0.65 | 6.0e-04 |
ETFA | NSAA score | 25 | 0.71 | 7.1e-05 | 22 | –0.53 | 0.012 | 45 | 0.50 | 5.0e-04 | 30 | –0.40 | 0.05 |
6MWD | 34 | 0.49 | 0.003 | 26 | 0.66 | 3.0e-04 | ND | ND | ND | 24 | 0.64 | 1.4e-04 | |
MDH2 | NSAA score | 25 | 0.70 | 9.5e-05 | 22 | –0.50 | 0.017 | 45 | 0.56 | 6.3e-05 | 24 | –0.40 | 0.06 |
10MWT | 45 | –0.52 | 3.0e-04 | 16 | –0.54 | 0.032 | ND | ND | ND | 18 | –0.41 | 0.09 | |
6MWD | 34 | 0.47 | 0.005 | 26 | 0.62 | 8.0e-04 | ND | ND | ND | 30 | 0.50 | 0.005 |
Spearman rank correlation coefficient ρ was calculated for each protein biomarker per sample collection. Biomarkers correlating with outcome of physical tests as NSAA score, 6MWD and 10MWT with ρ > 0.50 or ρ<–0.50 in at least 2 sample collections and P-values < 0.05 were included.